New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

My recommendation is to begin with first principles by thoroughly understanding the core job your customer needs to ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

SAN JOSE, Antique (PIA) — The municipality of Tobias Fornier recently activated its Barangay Information Officers (BIO) ...

Dear reader, 2025 hasn't been an entirely bright year for the U.S. stock market. IPO opportunities have dried up, the FDA is ...

We've already seen antibacterial surfaces that kill microbes on contact, but scientists in the UK have recently gone a ...

It follows a previous report showing that the Werner syndrome protein WRN and its interacting protein WRNIP1 are indispensable for translesion DNA synthesis (TLS) by Y-family DNA polymerases (Pols).

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay under exposure to ...